Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation

Breast Cancer Research

Volumn 12, Issue 5, 2010, Pages

  Leslie, Kenneth ^a   Gao, Sizhi P ^a   Berishaj, Marjan ^a   Podsypanina, Katrina ^c   Ho, Hao ^b   Ivashkiv, Lionel ^b   Bromberg, Jacqueline ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; RAS PROTEIN; SHORT HAIRPIN RNA; STAT3 PROTEIN; TYROSINE; UVOMORULIN; CADHERIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN, MOUSE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL STRAIN; CELL STRAIN 293 T; CELL STRAIN MCF 10A RAS; CELL TRANSFORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE RAS; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; CANCER INVASION; CELL LINE; CELL MOTION; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; CADHERINS; CELL LINE, TRANSFORMED; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; INTERLEUKIN-6; JANUS KINASES; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RAS GTPASE-ACTIVATING PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 77957365010     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2725     Document Type: Article

References (71)

1. Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004, 165:1449-1460. 1618660, 15509516.
2. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105. 10.1038/nrc1275, 14964307.
3. Darnell JE. STATs and gene regulation. Science 1997, 277:1630-1635. 10.1126/science.277.5332.1630, 9287210.
4. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142. 150969, 11994401.
5. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006, 12:20-28. 10.1158/1078-0432.CCR-04-1749, 16397019.
6. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, Bornmann W, Bromberg JF. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007, 9:R32. 10.1186/bcr1680, 1929096, 17531096.
7. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007, 117:3660-3663. 10.1172/JCI34237, 2096452, 18060028.
8. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629. 10.1038/nm1249, 15895073.
9. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004, 114:720-728. 514583, 15343391.
10. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 2006, 172:245-257. 10.1083/jcb.200503021, 2063554, 16401721.
11. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005, 65:939-947.
12. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 2007, 21:1396-1408. 10.1101/gad.1553707, 1877751, 17510282.
13. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993, 366:643-654. 10.1038/366643a0, 8259209.
14. Clair T, Miller WR, Cho-Chung YS. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 1987, 47:5290-5293.
15. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995, 35:133-144. 10.1007/BF00694753, 7612899.
16. Watson DM, Elton RA, Jack WJ, Dixon JM, Chetty U, Miller WR. The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 1991, 17:161-169. 10.1007/BF01806365, 2039838.
17. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998, 18:2553-2558.
18. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998, 18:2545-2552. 110634, 9566874.
19. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 2004, 101:10602-10607. 10.1073/pnas.0404100101, 489981, 15249664.
20. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716. 10.1126/science.1171721, 2840701, 19556508.
21. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol 1995, 254:3-20. full_text, 8531694.
22. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 2006, 281:14111-14118. 10.1074/jbc.M511797200, 16571725.
23. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007, 21:1714-1719. 10.1101/gad.1549407, 1920165, 17639077.
24. Wen Z, Zhong Z, Darnell JE. Maximal activation of transcription of Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250. 10.1016/0092-8674(95)90311-9, 7543024.
25. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Current Protocols in Molecular Biology 1994, New York: John Wiley and Sons, Inc.
26. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. Stat3 as an oncogene. Cell 1999, 98:295-303. 10.1016/S0092-8674(00)81959-5, 10458605.
27. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268. 10.1016/S1046-2023(03)00032-X, 12798140.
28. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996, 93:11382-11388. 10.1073/pnas.93.21.11382, 38066, 8876144.
29. Chen HC. Boyden chamber assay. Methods Mol Biol 2005, 294:15-22.
30. Keely PJ, Fong AM, Zutter MM, Santoro SA. Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci 1995, 108:595-607.
31. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995, 1:792-797. 10.1038/nm0895-792, 7585182.
32. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856. 10.1172/JCI31871, 2096430, 18060032.
33. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6075-6086.
34. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001, 15:50-65. 10.1101/gad.828901, 312602, 11156605.
35. Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR, Salomon DS. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog 1992, 6:43-52. 10.1002/mc.2940060108, 1354442.
36. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005, 386:193-205. 10.1515/BC.2005.025, 15843165.
37. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002. 10.1172/JCI32533, 2096439, 18060036.
38. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947. 10.1038/onc.2009.180, 19581928.
39. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol 2007, 27:4444-4453. 10.1128/MCB.02404-06, 1900039, 17438134.
40. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005, 65:2532-2536. 10.1158/0008-5472.CAN-04-2425, 15805244.
41. Selander KS, Li L, Watson L, Merrell M, Dahmen H, Heinrich PC, Muller-Newen G, Harris KW. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 2004, 64:6924-6933. 10.1158/0008-5472.CAN-03-2516, 15466183.
42. Arulanandam R, Geletu M, Feracci H, Raptis L. Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration. Exp Cell Res 2010, 316:875-886. 10.1016/j.yexcr.2009.10.017, 19852956.
43. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ, Wang LH. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 2008, 283:14665-14673. 10.1074/jbc.M707429200, 2386910, 18353781.
44. Yamashita S, Miyagi C, Fukada T, Kagara N, Che YS, Hirano T. Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature 2004, 429:298-302. 10.1038/nature02545, 15129296.
45. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008. 10.1038/sj.onc.1205260, 11960372.
46. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24:5552-5560. 10.1038/sj.onc.1208719, 16007214.
47. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004, 64:3550-3558. 10.1158/0008-5472.CAN-03-3959, 15150111.
48. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992, 89:9064-9068. 10.1073/pnas.89.19.9064, 50065, 1384042.
49. Weaver VM, Howlett AR, Langton-Webster B, Petersen OW, Bissell MJ. The development of a functionally relevant cell culture model of progressive human breast cancer. Semin Cancer Biol 1995, 6:175-184. 10.1006/scbi.1995.0021, 7495986.
50. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216. 10.1016/S1535-6108(02)00125-3, 2788997, 12242153.
51. Imbalzano KM, Tatarkova I, Imbalzano AN, Nickerson JA. Increasingly transformed MCF-10A cells have a progressively tumor-like phenotype in three-dimensional basement membrane culture. Cancer Cell Int 2009, 9:7. 10.1186/1475-2867-9-7, 2666639, 19291318.
52. Kishimoto T. Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol 2005, 23:1-21. 10.1146/annurev.immunol.23.021704.115806, 15771564.
53. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar WL. Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004, 61:354-370. 10.1002/pros.20113, 15389813.
54. Bhat-Nakshatri P, Newton TR, Goulet R, Nakshatri H. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha. Proc Natl Acad Sci USA 1998, 95:6971-6976. 10.1073/pnas.95.12.6971, 22705, 9618523.
55. Galien R, Evans HF, Garcia T. Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding sites in interleukin-6 promoter inhibition by estrogens. Mol Endocrinol 1996, 10:713-722. 10.1210/me.10.6.713, 8776731.
56. Nettles KW, Gil G, Nowak J, Metivier R, Sharma VB, Greene GL. CBP is a dosage dependent regulator of NF{kappa}B suppression by the estrogen receptor. Mol Endocrinol 2007, 22:263-272. 10.1210/me.2007-0324, 2234588, 17932106.
57. Wang LH, Yang XY, Mihalic K, Xiao W, Li D, Farrar WL. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem 2001, 276:31839-31844. 10.1074/jbc.M105185200, 11429412.
58. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999, 20:435-459. 10.1210/er.20.4.435, 10453354.
59. Wang LH, Yang XY, Zhang X, Farrar WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood 2007, 110:4373-4384. 10.1182/blood-2006-07-038026, 2234797, 17785586.
60. Wang LH, Yang XY, Zhang X, Huang J, Hou J, Li J, Xiong H, Mihalic K, Zhu H, Xiao W, Farrar WL. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity 2004, 20:205-218. 10.1016/S1074-7613(04)00030-5, 14975242.
61. Zhao W, Liu M, Kirkwood KL. p38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem 2008, 283:1778-1785. 10.1074/jbc.M707573200, 2806577, 18042545.
62. Paschoud S, Dogar AM, Kuntz C, Grisoni-Neupert B, Richman L, Kuhn LC. Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1. Mol Cell Biol 2006, 26:8228-8241. 10.1128/MCB.01155-06, 1636780, 16954375.
63. Karadag A, Zhou M, Croucher PI. ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. Blood 2006, 107:3271-3278. 10.1182/blood-2005-09-3830, 1895758, 16373656.
64. Pulai JI, Chen H, Im HJ, Kumar S, Hanning C, Hegde PS, Loeser RF. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 2005, 174:5781-5788. 2903737, 15843581.
65. Lubin FD, Segal M, McGee DW. Regulation of epithelial cell cytokine responses by the alpha3beta1 integrin. Immunology 2003, 108:204-210. 10.1046/j.1365-2567.2003.01577.x, 1782878, 12562329.
66. Spencer VA, Xu R, Bissell MJ. Gene expression in the third dimension: the ECM-nucleus connection. J Mammary Gland Biol Neoplasia 2010, 15:65-71. 10.1007/s10911-010-9163-3, 20107877.
67. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, Huang T, Chan MW, Marini FC, Rosol TJ, Bonafe M, Hall BM. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008, 68:9087-9095. 10.1158/0008-5472.CAN-08-0400, 18974155.
68. Coulie PG, Stevens M, Van Snick J. High- and low-affinity receptors for murine interleukin 6. Distinct distribution on B and T cells. Eur J Immunol 1989, 19:2107-2114. 10.1002/eji.1830191121, 2574680.
69. Inda MD, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010, 24:1731-1745. 10.1101/gad.1890510, 20713517.
70. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS, Gutkind JS. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006, 8:733-746. 10.1593/neo.06274, 1584297, 16984731.
71. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006, 66:3087-3095. 10.1158/0008-5472.CAN-05-3447, 16540658.